|
 The Indian Council of Medical Research (ICMR) has invited Expression of Interest (EoI) from the eligible companies for commercialization of technology for Leishmania disease testing.
Leishmaniasis is commonly known as kala-azar (KA), which means “black disease”, referring to the greyish or blackish discoloration of the skin during infection, from the Hindi word for black (kala) and the Persian word for disease (azar).
ICMR will collaborate with companies for undertaking Transfer of technology and commercialization of “Plant Extract Based Composition Useful for Leishmania Promastigote,” useful in “Leishmania Promastigote Culture Drug Sensitivity Testing”.
Leishmaniasis is caused by protozoan parasites which are transmitted by the bite of infected female phlebotomine sandflies.
The ICMR – Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), one of the constituent Institutes of the ICMR, New Delhi has developed the technology entitled “Plant Extract Based Composition Useful for Leishmania Promastigote”.
The EoI document containing the details of qualification criteria, submission details, brief objective, scope of work and evaluation criteria etc. can be downloaded from the ICMR website.
Last date of submission is August 23, 2025
Applicants can submit their EoI through the Medical Innovation Patent Mitra Portal (https://patentmitra.icmr.org.in/companyeoiregistration/).
The company would be granted rights to undertake further development, manufacture, sell, and commercialize the Technology/Product “Plant Extract Based Composition Useful for Leishmania Promastigote”.
An Agreement following EoI is proposed to be executed on a Non-Exclusive basis with single/multiple companies to enable wider outreach of the “Plant Extract Based Composition Useful for Leishmania Promastigote” for societal benefit and public health use. All the related issues shall be governed by ICMR IP Policy, as revised and approved by the Competent Authority.
ICMR- RMRIMS will provide expert guidance and technical support for the production of “Plant Extract Based Composition Useful for Leishmania Promastigote”, in all phases. Such technical oversight by ICMR-RMRIMS would accelerate the development of the product and its commercialization.
ICMR would provide technical support through its team of experienced scientists in study planning, product development, development of study protocol, results/data analysis, outcome assessment, safety & efficacy assessment, product improvement, etc., if deemed fit upon the mutual understanding between ICMR and collaborative company.
ICMR through its Institutes would provide support and facilitation to conduct the R&D/clinical study of new technology/product in India through its affiliates/institutes, in collaboration with the company/institutions in a professional and mutually agreed-upon manner and timelines, which will be decided later under the Agreement. It would provide technical support in development of technology/ product and will also facilitate the validation, if required, as per the terms & conditions of the Agreement.
ICMR shall have no financial implications unless otherwise specified.
The company shall have valid provisions to provide all necessary infrastructure/material/manpower required for product development/ validation/scale-up either directly or otherwise. It shall have provisions to undertake the scale-up as required, manufacturing and commercialization of the “Plant Extract Based Composition Useful for Leishmania Promastigote”, in a set milestone.
The company agrees to share the technical data with ICMR and participate in all discussions in a professional and mutually agreed-upon manner. It shall agree to allow authorized personnel/scientist/team of ICMR to visit the designated lab/ production facility as and when required, as envisaged under this EoI and subsequent Agreement. It shall be responsible for obtaining all the regulatory approvals required for commercialization or starting from R&D for product development to its commercialization.
|